Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting
The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor
Ross C. Radusky¹, Jessica L. Feig², Bruce N. Cronstein³, Andrew G. Franks Jr.⁴ and Edwin SL Chan¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine. Department of Translational Medicine, New York University School of Medicine, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ⁴Dermatology & Medicine (Rheumatology), New York University, New York, NY
Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…
Abstract Number: 1712 • 2012 ACR/ARHP Annual Meeting
The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis
Elana J. Bernstein¹, Jessica K. Gordon², Robert F. Spiera², Lisa A. Mandl² and Evelyn M. Horn³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Cardiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY
Background/Purpose: Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg on right heart catheterization (RHC), is a leading cause of…
Abstract Number: 1505 • 2012 ACR/ARHP Annual Meeting
Inactivation of Tankyrases Ameliorates Canonical Wnt Signaling and Prevents Experimental Fibrosis
Alfiya Distler¹, Lisa Deloch², Jingang Huang², Clara Dees², Neng Yu Lin², Christian Beyer³, Oliver Distler⁴, Georg A. Schett⁵ and Joerg HW Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is characterized by aberrant activation of fibroblasts with increased release of extracellular matrix components. Canonical Wnt signaling has recently emerged as…
Abstract Number: 1464 • 2012 ACR/ARHP Annual Meeting
Comparison of Baseline Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis
Heather Gladue¹, Daniel Furst², Veronica Berrocal³, James R. Seibold⁴, Peter A. Merkel⁵, Maureen D. Mayes⁶, Kristine Phillips⁷, Robert W. Simms⁸, Shervin Assassi⁹, Philip J. Clements¹⁰, Paul Maranian¹¹ and Dinesh Khanna¹², ¹University of Michigan, Ann Arbor, MI, ²David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ³Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Scleroderma Research Consultants LLC, Avon, CT, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁸Rheumatology, Boston University School of Medicine, Boston, MA, ⁹Rheumatology, Univ of Texas Health Science Houston, Houston, TX, ¹⁰University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ¹¹Division of Rheumatology, UCLA Medical School, Los Angeles, CA, ¹²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Randomized clinical trials (RCTs) of treatment of diffuse systemic sclerosis (dcSSc) would benefit from a composite index that predicted efficacy better than current standard…
Abstract Number: 1470 • 2012 ACR/ARHP Annual Meeting
Clinical Features Associated with Anti-Th/to in Non-Scleroderma Patients – Sine Scleroderma?
Ann D. Chauffe¹, Minoru Satoh¹, Angela Ceribelli², Edward K.L. Chan², Yi Li¹, Eric S. Sobel³, Westley H. Reeves⁴ and Michael R. Bubb¹, ¹Medicine, University of Florida, Gainesville, FL, ²Oral Biology, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Autoantibodies in scleroderma (systemic sclerosis, SSc) such as anti-topoisomerase I (Scl-70), RNA polymerase III, centromere, U3RNP/fibrillarin, and Th/To are associated with a unique subset…
Abstract Number: 853 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis Classification Criteria: Developing Methods for Multi-Criteria Decision Analysis
Sindhu R. Johnson¹, Raymond P. Naden², Jaap Fransen³, Frank H.J. van den Hoogen⁴, Janet E. Pope⁵, Murray Baron⁶, Alan G. Tyndall⁷, Marco Matucci-Cerinic⁸ and Dinesh Khanna on behalf of ACR/EULAR Classification Criteria SSc⁹, ¹Dept of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Auckland City Hospital, Auckland, New Zealand, Austria, ³Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁷Rheumatology, University of Basel, Basel, Switzerland, ⁸Medicine, Univ Florence, Firenze, Italy, ⁹Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Classification criteria for systemic sclerosis (SSc) are being developed. Twenty-three candidate criteria have been identified, but need to be reduced. The objectives of this…
Abstract Number: 711 • 2012 ACR/ARHP Annual Meeting
Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group
MIchelle Jung¹, Murray Baron², Marie Hudson³, Ashley Bonner⁴, Janet E. Pope⁵ and Canadian Scleroderma Research Group⁶, ¹Western University, London, ON, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Montreal, QC, Canada
Background/Purpose: Myopathy / myositis is associated with more severe systemic scleroderma (SSc). The aim of this study was to determine such clinical information from the…
Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting
Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Lada Miller¹, Sandra Chartrand¹, Martial Koenig², Jean-Richard Goulet³, Eric Rich¹, Michal Abrahamowicz⁴, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁴Centre Universitaire de Santé McGill (CUSM), Montreal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…
Abstract Number: 721 • 2012 ACR/ARHP Annual Meeting
Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis
Sandra Chartrand¹, Lada Miller¹, Martial Koenig², Jean-Richard Goulet¹, Eric Rich¹, Anne S. Chin³, Yves Provost³, Carl Chartrand-Lefebvre³, Pauline Gou¹, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Radiology, Hôtel-Dieu de Montréal du CHUM, Montréal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a major complication of systemic sclerosis (SSc). We observed that a significant proportion of our SSc patients with PH as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].